Harmony Biosciences Holdings, Inc. HRMY Business Segments — Allocated Share Based Compensation Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Harmony Biosciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Harmony Biosciences Holdings, Inc.'s business segments — allocated share based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Harmony Biosciences Holdings, Inc.'s business segments — allocated share based compensation expense?
- Harmony Biosciences Holdings, Inc. (HRMY) reported business segments — allocated share based compensation expense of $10.31M in Q1 2026.
- How has Harmony Biosciences Holdings, Inc.'s business segments — allocated share based compensation expense changed year-over-year?
- Harmony Biosciences Holdings, Inc.'s business segments — allocated share based compensation expense decreased by 17.2% year-over-year, from $12.45M to $10.31M.
- What is the long-term trend for Harmony Biosciences Holdings, Inc.'s business segments — allocated share based compensation expense?
- Over 3 years (2022 to 2025), Harmony Biosciences Holdings, Inc.'s business segments — allocated share based compensation expense has grown at a 18.7% compound annual growth rate (CAGR), from $26.91M to $44.96M.
- What does business segments — allocated share based compensation expense mean?
- This metric quantifies the portion of equity-based compensation expense attributed to personnel working within the rare neurological diseases segment. It highlights the cost of human capital and alignment of employee incentives with long-term shareholder value.